|
Investor Information
Vyteris Announces Growth Initiative Through Expanded Business Development Team 09.23.08
FAIR LAWN, N.J., Sep 23, 2008 (BUSINESS WIRE) -- Vyteris, Inc. (OTCBB: VYTR), developer and manufacturer of the first FDA-approved active patch transdermal drug delivery system (LidoSite(R)) and a leader in active transdermal drug delivery technology, announced the establishment of its Business Development Team. Vyteris' Business Development Team w...
Dutton Associates Announces Investment Opinion: Vyteris Rating Speculative Buy In Update By Dutton Associates 09.08.08
ROSEVILLE, Calif., Sep 08, 2008 (BUSINESS WIRE) -- Dutton Associates updates its coverage of Vyteris (OTCBB:VYTR) maintaining a Speculative Buy rating and a $1 price target. The 13-page report by Dutton senior analyst Richard W. West, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg Professional, FactSet, Capital IQ, Zacks...
Financial Results
|
|
| Delayed 20 minutes. |
| Last Trade: |
0.15 |
| Change: |
- 0.05
|
| % Change: |
- 25.000%
|
| Intraday Range: |
0.15 - 0.15 |
| Jan 6, 2009 9:30 AM ET |
| Stock Information >> |
|
|
|
